FDA approves Glaxo's GLP-1

Share this article:

GlaxoSmithKline's weekly GLP-1 diabetes injection has been approved. The FDA made the announcement Tuesday morning. The type-2 diabetes drug, known in past coverage as albiglutide, is officially called Tanzeum.

The FDA was initially set to review the drug in January but said last August that it needed more time to review “information submitted by GSK in response to the [FDA's] requests.”

The approval puts GSK's new drug in a fight for patients whose choices include Novo's Victoza and AstraZeneca's Byetta/Bydureon. BMS ceded it's interest in Byetta/Bydureon last year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.